Quinn Opportunity Partners LLC Sells 900 Shares of Allergan PLC. (AGN)

Quinn Opportunity Partners LLC lessened its stake in shares of Allergan PLC. (NYSE:AGN) by 4.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 17,650 shares of the company’s stock after selling 900 shares during the period. Quinn Opportunity Partners LLC’s holdings in Allergan PLC. were worth $4,291,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Jacobi Capital Management LLC grew its holdings in Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares during the period. JNBA Financial Advisors grew its holdings in Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after purchasing an additional 12 shares during the period. Pacific Center for Financial Services grew its holdings in Allergan PLC. by 805.1% during the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock valued at $128,000 after purchasing an additional 475 shares during the period. Ropes Wealth Advisors LLC grew its holdings in Allergan PLC. by 31.0% during the first quarter. Ropes Wealth Advisors LLC now owns 575 shares of the company’s stock valued at $137,000 after purchasing an additional 136 shares during the period. Finally, Hudock Capital Group LLC grew its holdings in Allergan PLC. by 0.4% during the second quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock valued at $138,000 after purchasing an additional 2 shares during the period. 82.02% of the stock is owned by institutional investors and hedge funds.

Several analysts have issued reports on AGN shares. ValuEngine lowered Allergan PLC. from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Cowen and Company set a $400.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. Mizuho cut their price target on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Royal Bank Of Canada set a $284.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Monday, June 12th. Finally, Cantor Fitzgerald started coverage on Allergan PLC. in a report on Friday, June 16th. They set a “neutral” rating and a $231.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $273.34.

ILLEGAL ACTIVITY NOTICE: “Quinn Opportunity Partners LLC Sells 900 Shares of Allergan PLC. (AGN)” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://transcriptdaily.com/2017/09/24/quinn-opportunity-partners-llc-sells-900-shares-of-allergan-plc-agn.html.

Shares of Allergan PLC. (AGN) opened at 204.65 on Friday. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The company has a 50 day moving average price of $229.79 and a 200-day moving average price of $236.07. The stock has a market capitalization of $68.42 billion, a P/E ratio of 6.24 and a beta of 1.18.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the previous year, the firm posted $3.35 EPS. Allergan PLC.’s revenue was up 8.8% compared to the same quarter last year. On average, analysts predict that Allergan PLC. will post $16.26 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were issued a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.37%. The ex-dividend date was Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply